| Literature DB >> 8262737 |
S A Taylor1, J Benedetti, D Schuller, S P Richman, G O Broun, A Hantel.
Abstract
Twenty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with piroxantrone 150 mg/m2 intravenously every 21 days. There were no objective responses. The 95% upper confidence bound for response is 15%. Primary toxicity was hematologic.Entities:
Mesh：
Substances：
Year: 1993 PMID： 8262737 DOI： 10.1007/bf00874161
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850